{"protocolSection": {"identificationModule": {"nctId": "NCT00779506", "orgStudyIdInfo": {"id": "D1443L00062"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)", "officialTitle": "A 8-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) With Daily Dose 400mg-800mg in the Treatment of Acute Schizophrenic Patients", "acronym": "QUENCH"}, "statusModule": {"statusVerifiedDate": "2010-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-11"}, "primaryCompletionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-22", "studyFirstSubmitQcDate": "2008-10-23", "studyFirstPostDateStruct": {"date": "2008-10-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-20", "resultsFirstSubmitQcDate": "2011-10-19", "resultsFirstPostDateStruct": {"date": "2011-11-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-10-19", "lastUpdatePostDateStruct": {"date": "2011-11-23", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients. The eligible patient will be assigned to study treatment with Quetiapine XR on Day 1.\n\nPLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA."}, "conditionsModule": {"conditions": ["Schizophrenia"], "keywords": ["Acute schizophrenia", "PANSS"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 96, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Quetiapine Fumarate XR", "type": "EXPERIMENTAL", "description": "Seroquel XR 400-800mg", "interventionNames": ["Drug: Quetiapine Fumarate XR"]}], "interventions": [{"type": "DRUG", "name": "Quetiapine Fumarate XR", "description": "oral, once daily, flexible dose", "armGroupLabels": ["Quetiapine Fumarate XR"], "otherNames": ["Seroquel XR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Change in Positive and Negative Syndrome Scale(PANSS)Total Score", "description": "PANSS, a 30-item scale where each symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme), total score is 30 - 210.\n\nDescription of the reporting Groups: Evaluate the efficacy of Quetiapine XR with daily dose 400 mg - 800 mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from baseline to Day 57 in total score of PANSS using the last observation carried forward (LOCF) method", "timeFrame": "From baseline to Day 57"}], "secondaryOutcomes": [{"measure": "Positive and Negative Syndrome Scale (PANSS) Positive Score", "description": "To evaluate the change of positive symptoms from baseline to Day 57 in PANSS positive score, a 7-item scale where eash symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme)", "timeFrame": "From baseline to Day 57"}, {"measure": "Positive and Negative Syndrome Scale (PANSS) Negative Score", "description": "To evaluate the change of negative symptoms from baseline to Day 57 in PANSS negative score, a 7-item scale where each symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme)", "timeFrame": "From baseline to Day 57"}, {"measure": "Positive and Negative Syndrome Scale (PANSS) General Psychopathology Score", "description": "To evaluate the change of general psychopathology symptoms from baseline to Day 57 in PANSS general score, a 16-item scale where each symptom is rated on a severity scale ranging from 1 (absent) to - 7 (extreme)", "timeFrame": "From baseline to Day 57"}, {"measure": "Clinical Global Impression (CGI) Score", "description": "The Clinical Global Impression - Severity (CGI-S) and - illness (CGI-I) is used in this study. The CGI-S is scored to rate the patient's current clinical state. The CGI-I is scored to rate the patient's change from baseline CGI. Each CGI item is scored on a scale from 1 to 7 (CGI-S: 1 = Normal, not ill, 7= Among the most extremely ill patients/ CGI-I: 1= very much improved, 7= very much worse). CGI-I scores greater than 4 indicate worsening, while scores less than 4 indicate improvement", "timeFrame": "From baseline to Day 57"}, {"measure": "Montgomery-Asberg Depression Rating Scale (MADRS) Total Score", "description": "To treat depressive symptoms in acute schizophrenic patients by evaluation of the change from baseline to day 67 in MADRS total score, a 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0-6 scale, higher MADRS scores indicate higher levels of depressive symptoms.", "timeFrame": "From baseline to Day 57"}, {"measure": "Global Assessment of Functioning (GAF) Score", "description": "To improve functional capability in acute schizophrenic patients by evaluation of the change from baseline to Day 57 in GAF scale score, a single-item rating scale for evaluating the overall functioning on a continuum from psychologic or psychiatric sickness to health.", "timeFrame": "From baseline to Day 57"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Documented clinical diagnosis meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria\n* PANSS total score of at least 70 at enrolment and at assignment Day 1\n* CGI Severity of Illness score of at least 4 (moderately ill) at enrolment and at assignment Day 1 and with worsening of the patient's condition during the 3 weeks\n\nExclusion Criteria:\n\n* Known intolerance or lack of response to quetiapine fumarate\n* Administration of a depot antipsychotic injection within one dosing interval (for the depot) before assignment\n* Substance or alcohol dependence at enrolment\n* Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrolment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "YounHoon Kim", "affiliation": "Inje University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research site", "city": "Ansan", "state": "Gyeonggi-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.32361, "lon": 126.82194}}, {"facility": "Research site", "city": "Gwangju", "state": "Gyeonggi-do", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Research site", "city": "Bugok", "state": "Gyeongsangnam-do", "country": "Korea, Republic of"}, {"facility": "Research site", "city": "Masan", "state": "Gyeongsangnam-do", "country": "Korea, Republic of", "geoPoint": {"lat": 35.12725, "lon": 126.83149}}, {"facility": "Research site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Research site", "city": "Pusan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Research site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "From 4 Nov 2008 to 9 July 2009, 96 subjects were enrolled from 9 centers in Korea", "groups": [{"id": "FG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "96"}]}, {"type": "Enrolled", "achievements": [{"groupId": "FG000", "numSubjects": "96"}]}, {"type": "Screen Failed", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Assigned", "achievements": [{"groupId": "FG000", "numSubjects": "94"}]}, {"type": "MITT", "achievements": [{"groupId": "FG000", "numSubjects": "89"}]}, {"type": "Treatment Complete", "achievements": [{"groupId": "FG000", "numSubjects": "67"}]}, {"type": "Withdrawal Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "27"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "67"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Screening Failed", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "89"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "35.8", "spread": "13"}]}]}, {"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "42.4", "spread": "9.8"}]}]}, {"title": "Total", "categories": [{"measurements": [{"groupId": "BG000", "value": "39.7", "spread": "11.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "37"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "52"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "23.7", "spread": "5.4"}]}]}, {"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "23.4", "spread": "3.5"}]}]}, {"title": "Total", "categories": [{"measurements": [{"groupId": "BG000", "value": "23.5", "spread": "4.4"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "158", "spread": "5.9"}]}]}, {"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "168.7", "spread": "6.6"}]}]}, {"title": "Total", "categories": [{"measurements": [{"groupId": "BG000", "value": "164.2", "spread": "8.2"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "59.1", "spread": "13"}]}]}, {"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "66.6", "spread": "11.4"}]}]}, {"title": "Total", "categories": [{"measurements": [{"groupId": "BG000", "value": "63.5", "spread": "12.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Change in Positive and Negative Syndrome Scale(PANSS)Total Score", "description": "PANSS, a 30-item scale where each symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme), total score is 30 - 210.\n\nDescription of the reporting Groups: Evaluate the efficacy of Quetiapine XR with daily dose 400 mg - 800 mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from baseline to Day 57 in total score of PANSS using the last observation carried forward (LOCF) method", "populationDescription": "The MITT set was used for primary analyses (89) participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "From baseline to Day 57", "groups": [{"id": "OG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-26.8", "spread": "4.2"}]}]}]}, {"type": "SECONDARY", "title": "Positive and Negative Syndrome Scale (PANSS) Positive Score", "description": "To evaluate the change of positive symptoms from baseline to Day 57 in PANSS positive score, a 7-item scale where eash symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme)", "populationDescription": "The MITT set was used for primary analyses (89) participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "From baseline to Day 57", "groups": [{"id": "OG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.4", "spread": "1.2"}]}]}]}, {"type": "SECONDARY", "title": "Positive and Negative Syndrome Scale (PANSS) Negative Score", "description": "To evaluate the change of negative symptoms from baseline to Day 57 in PANSS negative score, a 7-item scale where each symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme)", "populationDescription": "The MITT set was used for primary analyses (89) participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "From baseline to Day 57", "groups": [{"id": "OG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.2", "spread": "1.3"}]}]}]}, {"type": "SECONDARY", "title": "Positive and Negative Syndrome Scale (PANSS) General Psychopathology Score", "description": "To evaluate the change of general psychopathology symptoms from baseline to Day 57 in PANSS general score, a 16-item scale where each symptom is rated on a severity scale ranging from 1 (absent) to - 7 (extreme)", "populationDescription": "The MITT set was used for primary analyses (89) participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "From baseline to Day 57", "groups": [{"id": "OG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.2", "spread": "2.3"}]}]}]}, {"type": "SECONDARY", "title": "Clinical Global Impression (CGI) Score", "description": "The Clinical Global Impression - Severity (CGI-S) and - illness (CGI-I) is used in this study. The CGI-S is scored to rate the patient's current clinical state. The CGI-I is scored to rate the patient's change from baseline CGI. Each CGI item is scored on a scale from 1 to 7 (CGI-S: 1 = Normal, not ill, 7= Among the most extremely ill patients/ CGI-I: 1= very much improved, 7= very much worse). CGI-I scores greater than 4 indicate worsening, while scores less than 4 indicate improvement", "populationDescription": "The MITT set was used for primary analyses (89) participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "From baseline to Day 57", "groups": [{"id": "OG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.46", "spread": "0.25"}]}]}]}, {"type": "SECONDARY", "title": "Montgomery-Asberg Depression Rating Scale (MADRS) Total Score", "description": "To treat depressive symptoms in acute schizophrenic patients by evaluation of the change from baseline to day 67 in MADRS total score, a 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0-6 scale, higher MADRS scores indicate higher levels of depressive symptoms.", "populationDescription": "The MITT set was used for primary analyses (89) participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "From baseline to Day 57", "groups": [{"id": "OG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.44", "spread": "2"}]}]}]}, {"type": "SECONDARY", "title": "Global Assessment of Functioning (GAF) Score", "description": "To improve functional capability in acute schizophrenic patients by evaluation of the change from baseline to Day 57 in GAF scale score, a single-item rating scale for evaluating the overall functioning on a continuum from psychologic or psychiatric sickness to health.", "populationDescription": "The MITT set was used for primary analyses (89) participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "From baseline to Day 57", "groups": [{"id": "OG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.9", "spread": "2.9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Safety population who were taking at least one dose of study treatment were used for the safety analyses (94) participants", "eventGroups": [{"id": "EG000", "title": "Quetiapine XR", "description": "This is an 8-week, multi-centre, open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients", "seriousNumAffected": 0, "seriousNumAtRisk": 94, "otherNumAffected": 94, "otherNumAtRisk": 94}], "otherEvents": [{"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 94}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 94}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 94}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 94}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 94}]}, {"term": "Toothache", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 94}]}, {"term": "Sedation", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 94}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 94}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 94}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 94}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Retraction", "relevance": "HIGH"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}